# Biologic Overview

Biologic Overview – Hannah Lomzenski

Background

-   "-cept" refers to fusion of a receptor to the Fc part of human
    immunoglobulin G1 (IgG1)
-   "-mab" indicates a monoclonal antibody (mAb)
-   "-ximab" indicates a chimeric mAb
-   "-zumab" indicates a humanized mAb
-   "-umab" indicates a fully human mAb
-   “-tinib” indicates a tyrosine kinase inhibitor (TKIs are small
    molecule inhibitors rather than true biologics)

​​​​​​​

Kinase inhibition

| 0            | 1          | 2                          | 3                                | 4                                                                   |
|--------------|------------|----------------------------|----------------------------------|---------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action        | Common Uses                      | Common Side Effects                                                 |
| Tofacitinib  | Xeljanz    | JAK-1 and JAK-3 inhibitors | RA, UC, JIA, psoriatic arthritis | infections, nasopharyngitis, skin rash, GI sx, GU sx; \<1% lymphoma |
| Baracitinib  | Olumiant   | JAK-1 and JAK-2 inhibitor  | RA; off-label: COVID-19          | infections, URI, nausea, ÝAST/ALT; \<1% lymphoma                    |
| Upadacitinib | Rinvoq     | non-specific JAK inhibitor | RA                               | URI, nausea, neutropenia, ÝAST, ÝCPK                                |

IL-1 inhibition

| 0            | 1          | 2                                                                   | 3                                                                                                                                        | 4                                                                                             |
|--------------|------------|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action                                                 | Common Uses                                                                                                                              | Common Side Effects                                                                           |
| Anakinra     | Kineret    | IL-1 receptor antagonist                                            | IL-1 receptor antagonist deficiency, neonatal multi-system inflammatory Dz, RA; off-label: gout flares, FMF, recurrent pericarditis, HLH | HA, vomiting, infections, nasopharyngitis, Ab development; in RA: eosinophilia, decreased WBC |
| Canakinumab  | Ilaris     | mAb against IL-1β                                                   | cryoporin-associated periodic syndromes (CAPS), FMF, hyperimmunoglobin D syndrome, TRAPS; off-label: gout flare                          | weight gain, GI sx, HA, vertigo, serious infections                                           |
| Rilonacept   | Arcalyst   | binds to IL-1β (some binding of IL-1α and IL-1 receptor antagonist) | CAPS, deficiency of IL-1 receptor antagonist                                                                                             | URI, infections, hypoesthesia, Ab development                                                 |

TNF-inhibition

| 0            | 1          | 2                                                                      | 3                                                               | 4                                                                               |
|--------------|------------|------------------------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action                                                    | Common Uses                                                     | Common Side Effects                                                             |
| Adalilumab   | Humira     | mAb against TNFα                                                       | RA, IBD, AS, psoriasis, uveitis, hidradenitis suppurativa       | skin rash, HA, URI, infections, Ý CPK, +ANA titer (12%), Ab development (3-26%) |
| Certolizumab | Cimzia     | humanized mAb Fab fragment against TNFα                                | RA, Crohn’s, AS, psoriasis; \*approved for use during pregnancy | skin rash, nausea, URI, infections                                              |
| Etanercept   | Enbrel     | tumor necrosis factor receptor linked to Fc portion of IgG1; binds TNF | RA, AS, psoriasis, JIA                                          | skin rash, diarrhea, infections, +ANA titer (11%)                               |
| Infliximab   | Remicade   | chimeric mAb against TNFα                                              | RA, IBD, AS, psoriasis                                          | abd pain, URI sx, anemia, Ý ALT, Ab development (10-50%), infections            |
| Golimumab    | Simponi    | mAb against TNFα                                                       | RA, UC, AS, psoriasis, JIA                                      | URI, infections, Ab development (16-38%), +ANA titer (4-17%)                    |

IL-17 inhibition

| 0            | 1          | 2                             | 3             | 4                                                            |
|--------------|------------|-------------------------------|---------------|--------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action           | Common Uses   | Common Side Effects                                          |
| Secukinumab  | Cosentyx   | human IgG1 mAb against IL-17A | AS, psoriasis | infections, nasopharyngitis, GI, IBD (\<1%)                  |
| Ixekizumab   | Taltz      | human IgG4 mAb against IL-17A | AS, psoriasis | neutropenia, Ab development, infections, URI, Crohn’s (\<1%) |

Costimulation blockade

| 0            | 1          | 2                                                                                                                          | 3                  | 4                                                |
|--------------|------------|----------------------------------------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action                                                                                                        | Common Uses        | Common Side Effects                              |
| Abatacept    | Orencia    | inhibits T-cell activation by binding CD80 and CD86 on APCs, thus blocking the required CD28 ixn between APCs and T cells. | RA, psoriasis, JIA | nausea, UTI, HA, infections, URI, Ab development |

B-cell depletion and inhibition

| 0            | 1          | 2                                                                                                                                                                     | 3                                                                                                                                                        | 4                                                                                                                                                |
|--------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action                                                                                                                                                   | Common Uses                                                                                                                                              | Common Side Effects                                                                                                                              |
| Rituximab    | Rituxan    | mAb against the CD20 antigen on surface of B-lymphocytes                                                                                                              | CLL, Non-Hodgkin lymphomas, GPA, microscopic polyangiitis, pemphigus vulgaris, RA; many off-label uses (GvHD, lupus nephritis, MG, neuromyelitis optica) | HTN, peripheral edema, night sweats, fever, weight gain, angioedema, arthralgias, Ý ALT, infections, hypophosphatemia, hematologic abnormalities |
| Belimumab    | Benlysta   | IgG1-lambda mAb that prevents survival of B-lymphocytes by blocking the binding of soluble human B lymphocyte stimulator protein (BLyS) to receptors on B lymphocytes | lupus nephritis, SLE                                                                                                                                     | GI sx, hypersensitivity rxn, infections, psychiatric disturbances                                                                                |

IL-6 inhibition

| 0            | 1          | 2                                                   | 3                                                        | 4                                                                  |
|--------------|------------|-----------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action                                 | Common Uses                                              | Common Side Effects                                                |
| Tocilizumab  | Actemra    | IL-6 receptor antagonist                            | cytokine release syndrome, giant cell arteritis, RA, JIA | Ý serum cholesterol, Ý AST/ALT, infusion rxn, HSV infection (\<2%) |
| Sarilumab    | Kevzara    | IL-6 receptor antagonist (soluble + membrane-bound) | RA                                                       | Ý AST/ALT, HSV infection (\<2%)                                    |

IL-12/23 inhibition

| 0            | 1          | 2                            | 3              | 4                                                                        |
|--------------|------------|------------------------------|----------------|--------------------------------------------------------------------------|
| Generic Name | Brand Name | Mechanism of Action          | Common Uses    | Common Side Effects                                                      |
| Ustekinumab  | Stelara    | mAb against IL-12 + IL-23    | IBD, psoriasis | infections, nasopharyngitis, Ab development, acne vulgaris, GI sx, GU sx |
| Guselkumab   | Tremfya    | human IgG1 mAb against IL-23 | psoriasis      | infections, URI, tinea, GI sx                                            |
